Weatherbie Capital’s BioMarin Pharmaceuticals BMRN Stock Holding History

Weatherbie Capital’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$215K	Sell	2,590 -908	-26%	-$78.1K	0.03%	61
2016 Q3	$324K	Buy	+3,498	New	+$329K	0.04%	61
2016 Q1	–	Sell	-5,435	Closed	-$569K	–	68
2015 Q4	$569K	Buy	5,435 +1,600	+42%	+$167K	0.07%	65
2015 Q3	$404K	Buy	3,835 +1,106	+41%	+$148K	0.05%	63
2015 Q2	$373K	Buy	2,729 +103	+4%	+$12.8K	0.04%	66
2015 Q1	$327K	Sell	2,626 -4,783	-65%	-$507K	0.03%	59
2014 Q4	$670K	Sell	7,409 -6,550	-47%	-$545K	0.06%	64
2014 Q3	$1.01M	Sell	13,959 -5,688	-29%	-$374K	0.09%	57
2014 Q2	$1.22M	Buy	19,647 +252	+1%	+$15.2K	0.11%	62
2014 Q1	$1.32M	Sell	19,395 -648	-3%	-$47.8K	0.13%	66
2013 Q4	$1.41M	Sell	20,043 -3	-0%	-$204	0.13%	64
2013 Q3	$1.45M	Sell	20,046 -112,896	-85%	-$7.5M	0.13%	61
2013 Q2	$7.41M	Buy	+132,942	New	+$8.28M	0.77%	57

Other funds holding BMRN

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Weatherbie Capital's BMRN Position: Q4 2016 in Review

Weatherbie Capital reduced its BioMarin Pharmaceuticals (BMRN) stake by 26% in Q4 2016, selling an estimated $78.1K and leaving 2,590 shares worth $215K. The position accounts for 0.03% of the portfolio, ranked #61.

Weatherbie Capital first reported a position in BMRN in Q2 2013 and has held it in 13 quarters since. The position peaked at $7.41M in Q2 2013. 415 funds tracked by Wall St. Rank hold BMRN as of Q4 2016.

Weatherbie Capital held 2,590 shares of BioMarin Pharmaceuticals worth $215K as of Q4 2016.
Weatherbie Capital sold 908 BioMarin Pharmaceuticals shares in Q4 2016, an estimated $78.1K.
BioMarin Pharmaceuticals made up 0.03% of Weatherbie Capital's portfolio in Q4 2016, its #61 holding.
Weatherbie Capital first reported a position in BioMarin Pharmaceuticals in Q2 2013 and has held it in 13 quarters since.
Weatherbie Capital's BioMarin Pharmaceuticals position peaked at $7.41M in Q2 2013.
415 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q4 2016.

Based on Weatherbie Capital's 13F filing for Q4 2016, filed 14 Feb 2017.